Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Amortizatization of Intangibles (2022 - 2025)

Cytek Biosciences (CTKB) has disclosed Amortizatization of Intangibles for 4 consecutive years, with $1.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Amortizatization of Intangibles rose 29.31% year-over-year to $1.1 million, compared with a TTM value of $4.4 million through Dec 2025, up 34.11%, and an annual FY2025 reading of $4.4 million, up 34.11% over the prior year.
  • Amortizatization of Intangibles was $1.1 million for Q4 2025 at Cytek Biosciences, roughly flat from $1.1 million in the prior quarter.
  • Across five years, Amortizatization of Intangibles topped out at $1.1 million in Q4 2025 and bottomed at $672000.0 in Q2 2024.
  • Average Amortizatization of Intangibles over 4 years is $876437.5, with a median of $798000.0 recorded in 2023.
  • The sharpest move saw Amortizatization of Intangibles dropped 28.01% in 2023, then surged 63.39% in 2025.
  • Year by year, Amortizatization of Intangibles stood at $1.1 million in 2022, then decreased by 28.01% to $794000.0 in 2023, then increased by 11.71% to $887000.0 in 2024, then grew by 29.31% to $1.1 million in 2025.
  • Business Quant data shows Amortizatization of Intangibles for CTKB at $1.1 million in Q4 2025, $1.1 million in Q3 2025, and $1.1 million in Q2 2025.